B.R.A.I.N. Biotechnology Research and Information Network AG (DE:BNN)
XETRA:BNN
Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.50
€0.00(0.00%)
At close: 4:00 PM EST
€2.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.81 - €3.89
Previous CloseN/A
Volume750.00
Average Volume (3M)10.93K
Market Cap
€59.21M
Enterprise Value€64.57M
Total Cash (Recent Filing)€6.32M
Total Debt (Recent Filing)€24.03M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding21,847,494
10 Day Avg. Volume22,707
30 Day Avg. Volume10,926
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€55.79M
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn improving gross margin (2025 vs 2024) signals better production economics or product mix control. Over the next 2–6 months this can sustainably support operating leverage if maintained, giving management room to focus on reducing structural losses and funding R&D without proportionate revenue growth.
Free Cash Flow ImprovementA less-negative free cash flow in 2025 indicates partial improvement in cash conversion. This durable trend reduces near-term external funding pressure, improves negotiating leverage with lenders/investors, and if continued can restore liquidity buffers and lower dilution risk over the medium term.
Low Market Volatility (beta)A low beta implies the stock is less sensitive to market swings, which can make capital raises and strategic planning easier by reducing the likelihood of abrupt funding-cost spikes. This lower systematic volatility supports steadier access to equity/debt markets during multi-month financing or restructuring efforts.
Bears Say
Persistent Losses And Revenue DeclineOngoing net losses combined with consecutive revenue declines undermine the sustainability of the business model. Over a 2–6 month horizon, continued top-line deterioration makes path to profitability uncertain, elevates funding needs, and weakens the firm's ability to invest in growth or defend competitive positioning.
Weakened Balance Sheet And Higher LeverageA sharp rise in leverage from a steep equity decline reduces financial flexibility and raises refinancing and dilution risk. Structurally, higher debt servicing burden can crowd out R&D and commercialization spending and increase vulnerability to adverse funding conditions over the medium term.
Consistent Negative Operating Cash FlowPersistent negative operating cash flow shows the core business consumes cash rather than funds itself. Even with slight FCF improvement, reliance on external capital remains. This chronic cash shortfall creates ongoing refinancing risk and can force dilutive fundraising or curtailed operations over months.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €1.80 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €59.21M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Aug 27, 2026 which is in 76 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on May 28, 2026. The company reported -€0.29 earnings per share for the quarter, missing the consensus estimate of -€0.09 by -€0.2.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.29 in its last earnings report, missing expectations of -€0.09. Following the earnings report the stock price went up 2.062%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
-1361.43%
Trailing 12-Months
Asset Growth
-25.24%
Trailing 12-Months
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.